Skip to search formSkip to main contentSkip to account menu

immucillin H

Known as: 1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-iminoribitol, Forodesine, ImmH cpd 
A substance being studied in the treatment of some types of leukemia and lymphoma. It is a type of purine nucleoside phosphorylase (PNP) inhibitor.
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

BCX1777

Broader (2)

Purine NucleosidesPyrimidinones
forodesine hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Serum 25-dihydroxyvitamin D levels correlate with CD4(+)Foxp3(+) T-cell numbers in moderate/severe asthma.
Review
2011
Review
2011
New drug therapies in peripheral T-cell lymphoma
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous collection of lymphomas that are associated with very poor prognosis… 
2009
2009
Long-term treatment of CTCL with the oral PNP inhibitor, forodesine.
8552 Background: Forodesine is a potent inhibitor of purine nucleoside phosphorylase (PNP) that leads to T-cell selective… 
Review
2009
Review
2009
Novel therapies for peripheral T-cell non-Hodgkin's lymphomas
Purpose of reviewTo review new agents under investigation for the treatment of patients with peripheral T-cell lymphoma. Recent… 
Review
2007
Review
2007
Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
The search for more effective and safer anti-leukemia therapies has led to the identification of several new agents that show… 
2006
2006
Forodesine IV (Bcx-1777) Is Clinically Active in Relapsed/Refractory T-Cell Leukemia: Results of a Phase II Study (Interim Report).
Background: Forodesine, a potent, rationally designed purine nucleoside phosphorylase inhibitor, has shown clinical activity in T… 
2006
2006
Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.
Abstract Background: Forodesine is a potent, rationally designed purine nucleoside phosphorylase (PNP) inhibitor that is orally… 
2004
2004
Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma.
The profound suppression of T-cell immunity seen in patients with an inherited PNP deficiency supports the potential application… 
2004
2004
Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Phase I/II Studies in Patients with B-Cell Acute Lymphoblastic Leukemia.
Forodesine is a potent, specific transition-state analog inhibitor of PNP with clinical activity in T-cell malignancies… 
Highly Cited
2003
Highly Cited
2003
Crystal structure of human purine nucleoside phosphorylase complexed with acyclovir.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)